Ocular Therap (OCUL.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec8

Ocular Therapeutix plans to expedite FDA application for Axpaxli

12:26

Nov4

Tara Bankerford Gives Ocular Therapeutix a Buy Rating

16:36

Ocular Therap released FY2025 Q3 earnings on November 4 Pre-Market EST, actual revenue USD 14.54 M (forecast USD 14.57 M), actual EPS USD -0.3799 (forecast USD -0.3718)

14:30

Ocular Therap released FY2025 9 Months earnings on November 4 Pre-Market (EST), actual revenue USD 38.7 M, actual EPS USD -1.1529

14:30

Ocular Therapeutix Completes Equity Financing and Reaches Randomization Goal for Wet AMD Trial

12:20

Oct30

Tara Bancroft Gives Ocular Therapeutix a Buy Rating

10:32

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 14.54 M, Net Income -69.42 M, EPS -0.3799

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 13.46 M, Net Income -67.81 M, EPS -0.3929

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 10.7 M, Net Income -64.05 M, EPS -0.38

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change